Cerebroside sulfatase

Drug Profile

Cerebroside sulfatase

Alternative Names: Arylsulfatase A; HGT-1110; HGT-1111; Metazym; Recombinant human arylsulfatase A; Recombinant human cerebroside sulfatase; Recombinant human sulfatidate sulfatase; rhASA; SHP-611; Sulfatide sulfatase

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zymenex A/S
  • Developer Assistance Publique Hopitaux de Paris; Shire; Zymenex A/S
  • Class Arylsulfatases; Recombinant proteins
  • Mechanism of Action Cerebroside sulfatase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Metachromatic leukodystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Metachromatic leukodystrophy

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Jan 2017 Shire completes a phase I/II trial in Metachromatic leukodystrophy (Intrathecal) in Australia, Denmark, Japan, France and Germany (NCT01510028)
  • 05 Aug 2016 Cerebroside sulfatase is still in phase I/II trials for Metachromatic leukodystrophy (In children) in Australia, Japan, Denmark, France and Germany (Shire Form 10-Q, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top